<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">rpmj</journal-id><journal-title-group><journal-title xml:lang="ru">Research'n Practical Medicine Journal</journal-title><trans-title-group xml:lang="en"><trans-title>Research and Practical Medicine Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="epub">2410-1893</issn><publisher><publisher-name>"QUASAR", LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17709/2410-1893-2022-9-4-9</article-id><article-id custom-type="elpub" pub-id-type="custom">rpmj-839</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Оригинальные статьи. Урология и андрология</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Original Articles. Urology</subject></subj-group></article-categories><title-group><article-title>Прогностическая значимость логистической регрессионной модели для оценки риска рецидива у больных раком предстательной железы после радикальной простатэктомии</article-title><trans-title-group xml:lang="en"><trans-title>Prognostic significance of the logistic regression model for assessing the risk of recurrence in patients with prostate cancer after radical prostatectomy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5183-5153</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Рева</surname><given-names>С. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Reva</surname><given-names>S. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Рева Сергей Александрович – кандидат медицинских наук, заведующий онкологическим отделением № 6 (андрологии и онкоурологии) НИЦ Урологии, ассистент кафедры онкологии ФПО</p><p>198332, г. Санкт-Петербург, ул. Льва Толстого, д. 6-8 </p><p>SPIN: 8021-1510,</p><p>AuthorID: 801853</p></bio><bio xml:lang="en"><p>Sergey A. Reva – Cand. Sci. (Med.), head of the department of oncology No. 6 (of andrology and oncourology), Research Institute of Urology, assistant of the department of oncology</p><p>6-8 Lva Tolstogo street, Saint-Petersburg 198332</p><p>SPIN: 8021-1510,</p><p>AuthorID: 801853</p></bio><email xlink:type="simple">sgreva79@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3550-0067</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Арнаутов</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Arnautov</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Арнаутов Александр Валерьевич – врач–уролог онкологического отделения № 6 (андрологии и онкоурологии) НИЦ Урологии</p><p>Санкт-Петербург</p></bio><bio xml:lang="en"><p>Aleksander V. Arnautov – Urologist of the Department of oncology No. 6 (of andrology and oncourology), Research Institute of Urology</p><p>Saint-Petersburg</p></bio><email xlink:type="simple">av-arnautov@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2686-8786</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Клиценко</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Klitsenko</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Клиценко Ольга Анатольевна – кандидат биологических наук, доцент кафедры педагогики, философии и права</p><p>Санкт-Петербург</p><p>SPIN: 7354-3080,</p><p>AuthorID: 344162</p></bio><bio xml:lang="en"><p>Olga A. Klitsenko – Cand. Sci. (Biol.), associate professor of the Department of Pedagogy, Philosophy and Law</p><p>Saint-Petersburg</p><p>SPIN: 7354-3080,</p><p>AuthorID: 344162</p></bio><email xlink:type="simple">olkl@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3460-3427</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Петров</surname><given-names>С. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Petrov</surname><given-names>S. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Петров Сергей Борисович – доктор медицинских наук, профессор, руководитель клиники урологии ФПО</p><p>Санкт-Петербург</p><p>SPIN: 2230-2519,</p><p>AuthorID: 938083,</p><p>Scopus Author ID: 56624014200</p></bio><bio xml:lang="en"><p>Sergey B. Petrov – Dr. Sci. (Med.), professor, head of the research institute of urology</p><p>Saint-Petersburg</p><p>SPIN: 2230-2519,</p><p>AuthorID: 938083,</p><p>Scopus Author ID: 56624014200</p></bio><email xlink:type="simple">petrov-uro@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ПСПбГМУ им. акад. И. П. Павлова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Pavlov First St. Petersburg State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>СЗГМУ им. И. И. Мечникова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Mechnikov North-West State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>05</day><month>12</month><year>2022</year></pub-date><volume>9</volume><issue>4</issue><fpage>96</fpage><lpage>105</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Рева С.А., Арнаутов А.В., Клиценко О.А., Петров С.Б., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Рева С.А., Арнаутов А.В., Клиценко О.А., Петров С.Б.</copyright-holder><copyright-holder xml:lang="en">Reva S.A., Arnautov A.V., Klitsenko O.A., Petrov S.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.rpmj.ru/rpmj/article/view/839">https://www.rpmj.ru/rpmj/article/view/839</self-uri><abstract><sec><title>Цель исследования</title><p>Цель исследования. Изучение влияния факторов риска рецидива рака предстательной железы (РПЖ) после радикального хирургического лечения на неблагоприятное течение рецидива заболевания с формированием из совокупности наиболее значимых факторов модели, отражающей вероятность наступления рецидива.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведён ретроспективный анализ клинических, патоморфологических и периоперационных параметров 803 больных раком предстательной железы (РПЖ), которым выполнено радикальное хирургическое лечение в объеме радикальной простатэктомии. Средствами логистической регрессии была построена модель оценки риска рецидива для пациентов с РПЖ, в которую вошли 7 показателей, один из которых количественный (время между биопсией и началом лечения) и шесть категориальных (группа градации ISUP, cT, cN+, позитивный хирургический край, уровень простатического специфического антигена (ПСА) после операции, pN+). Построение логистической регрессионной модели заключалось в получении характеристик логистической функции Ψ для стандартного уравнения y = exp(ψ) / (1 + exp(ψ)).</p></sec><sec><title>Результаты</title><p>Результаты. Определив коэффициенты для каждого из показателей, получено Ψ для оценки риска рецидива Ψ = 0,485 × X1 + 1,937 × X2 + 0,789 × X3 + 3,229 × X4 + 0,443 × X5 + 0,880 × X6 + 0,015 × X7–6,65. В формуле каждый из коэффициентов регрессии описывает размер вклада соответствующего фактора и является положительными. Таким образом, каждый из факторов модели увеличивает общий риск рецидива. Качество полученной модели определено показателем хи-квадрат = 284,3; p &lt; 0,001; OR = 28,45. Чувствительность данной модели составила 86,6 %, специфичность – 81,5 %, диагностическая точность – 82,7 %.</p></sec><sec><title>Заключение</title><p>Заключение. Построенная модель позволяет оценить вероятность рецидива после радикального лечения (РПЭ) больных раком предстательной железы в зависимости от степени выраженности набора предиктивных факторов прогноз положительного эффекта дается при y &gt; 0,5, отрицательного при y ≤ 0,5, таких как группа градации ISUP, местная распространённость заболевания, клинически определяемое поражение лимфатических узлов, позитивный хирургический край, уровень ПСА через 1 мес. после операции более 0,09 нг/мл, наличие региональных метастазов, а также время между биопсией и началом лечения.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Purpose of the study</title><p>Purpose of the study. The study’s objective is to investigate the influence of risk factors for recurrence of prostate cancer (PCa) after radical surgical treatment on the unfavourable course of recurrence of the disease with the formation of a set of the most significant factors of a model that reflects the likelihood of relapse.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. A retrospective analysis of clinical, pathomorphological and perioperative parameters of 803 patients with PCa after radical prostatectomy was carried out. By means of logistic regression, a model for assessing the risk of recurrence for patients with prostate cancer was built, which included 7 indicators, one of which was measured by quantity (time between biopsy and start of treatment) and six categorical ones (ISUP grade group, cT, cN+, positive surgical margin, PSA level after surgery, pN+). The construction of a logistic regression model consisted in obtaining a characteristic of the logistic function Ψ for the standard equation y = exp(ψ) / (1 + exp(ψ)).</p></sec><sec><title>Results</title><p>Results. Substituting the coefficients obtained for each of the indicators, we obtain Ψ to assess the risk of relapse Ψ = 0.485 × X1+ 1.937 × X2 + 0.789 × X3 + 3.229 × X4 + 0.443 × X5 + 0.880 × X6 + 0.015 × X7–6.65. In the resulting formula, each of the regression coefficients describes the size of the contribution of the corresponding factor. In our case, all regression coefficients were positive, which means that this factor increases the overall risk of relapse. The quality of the resulting model is determined by the chi-square = 284.3; p &lt; 0.001; OR = 28.45. The sensitivity of this model was 86.6 %, specificity 81.5 %, diagnostic accuracy 82.7 %.</p></sec><sec><title>Conclusion</title><p>Conclusion. This model makes it possible to obtain the probability of recurrence after radical prostatectomy depending on the severity of a specific set of predictive signs (a positive effect is predicted for y &gt; 0.5, a negative one for y ≤ 0.5) and the degree of influence of one or a group of predictive signs on the likelihood of relapse, such as the ISUP grade group, locally advanced disease, clinically detectable lymph node lesion, positive surgical margin, PSA level of more than 0.09 ng/ml 1 month after surgery, the presence of regional metastases and the time between biopsy and the start of treatment.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>онкология</kwd><kwd>рак предстательной железы</kwd><kwd>биохимический рецидив</kwd><kwd>прогнозирование</kwd><kwd>безрецидивная выживаемость</kwd></kwd-group><kwd-group xml:lang="en"><kwd>oncology</kwd><kwd>prostate cancer</kwd><kwd>biochemical recurrence</kwd><kwd>prognosis</kwd><kwd>relapse-free survival</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021 Feb;79(2):243–262. https://doi.org/10.1016/j.eururo.2020.09.042</mixed-citation><mixed-citation xml:lang="en">Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol. 2021 Feb;79(2):243–262. https://doi.org/10.1016/j.eururo.2020.09.042</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969–974. https://doi.org/10.1001/jama.280.11.969</mixed-citation><mixed-citation xml:lang="en">D’Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998 Sep 16;280(11):969–974. https://doi.org/10.1001/jama.280.11.969</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Каприн А. Д., Костин А. А., Кульченко Н. Г., Толкачев А. О. Скрининг рака предстательной железы на основе многофакторного анализа. Вестник медицинского института “РЕАВИЗ”: реабилитация, врач и здоровье. 2014;(4(16));38–42.</mixed-citation><mixed-citation xml:lang="en">Kaprin AD, Kostin AA, Kulchenko NG, Tolkachev AO. Prostate cancer screening based on multivariate analysis. Bulletin of the medical Institute “REAVIZ”: rehabilitation, doctor and health. 2014;(4(16));38–42. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Morlacco A, Modonutti D, Motterle G, Martino F, Dal Moro F, Novara G. Nomograms in Urologic Oncology: Lights and Shadows. J Clin Med. 2021 Mar 2;10(5):980. https://doi.org/10.3390/jcm10050980</mixed-citation><mixed-citation xml:lang="en">Morlacco A, Modonutti D, Motterle G, Martino F, Dal Moro F, Novara G. Nomograms in Urologic Oncology: Lights and Shadows. J Clin Med. 2021 Mar 2;10(5):980. https://doi.org/10.3390/jcm10050980</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Ondracek RP, Kattan MW, Murekeyisoni C, Yu C, Kauffman EC, Marshall JR, et al. Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. J Natl Compr Canc Netw. 2016 Nov;14(11):1395–1401. https://doi.org/10.6004/jnccn.2016.0149</mixed-citation><mixed-citation xml:lang="en">Ondracek RP, Kattan MW, Murekeyisoni C, Yu C, Kauffman EC, Marshall JR, et al. Validation of the Kattan Nomogram for Prostate Cancer Recurrence After Radical Prostatectomy. J Natl Compr Canc Netw. 2016 Nov;14(11):1395–1401. https://doi.org/10.6004/jnccn.2016.0149</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Di Trapani E, Luzzago S, Peveri G, Catellani M, Ferro M, Cordima G, et al. A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging. Urol Oncol 2021 Jul;39(7):431.e15–431.e22. https://doi.org/10.1016/j.urolonc.2020.11.040</mixed-citation><mixed-citation xml:lang="en">Di Trapani E, Luzzago S, Peveri G, Catellani M, Ferro M, Cordima G, et al. A novel nomogram predicting lymph node invasion among patients with prostate cancer: The importance of extracapsular extension at multiparametric magnetic resonance imaging. Urol Oncol 2021 Jul;39(7):431.e15–431.e22. https://doi.org/10.1016/j.urolonc.2020.11.040</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Gandaglia G, Fossati N, Zaffuto E, Bandini M, Dell’Oglio P, Bravi CA, et al. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. Eur Urol. 2017 Oct;72(4):632–640. https://doi.org/10.1016/j.eururo.2017.03.049</mixed-citation><mixed-citation xml:lang="en">Gandaglia G, Fossati N, Zaffuto E, Bandini M, Dell’Oglio P, Bravi CA, et al. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. Eur Urol. 2017 Oct;72(4):632–640. https://doi.org/10.1016/j.eururo.2017.03.049</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Рева С. А., Носов А. К., Король В. Д., Арнаутов А. В., Зятчин И. В., Беркут М. В. и др. Результаты лечения больных раком предстательной железы высокого риска: мультицентровой анализ. Экспериментальная и клиническая урология. 2020;(3):36–42. https://doi.org/10.29188/2222-8543-2020-12-3-36-42</mixed-citation><mixed-citation xml:lang="en">Reva SA, Nosov AK, Korol VD, Arnautov AV, Zyatchin IV, Berkut MV, et al. Results of treatment of patients with high-risk prostate cancer: multicenter analysis. Experimental and Clinical Urology. 2020;(3):36–42. (In Russ.). https://doi.org/10.29188/2222-8543-2020-12-3-36-42</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Нюшко К. М., Алексеев Б. Я., Крашенинников А. А., Воробьев Н. В., Сафронова Е. Ю., Калпинский А. С. и др. Хирургическое лечение больных локализованным и местнораспространенным раком предстательной железы: результаты одноцентрового исследования. Онкология. Журнал им. П. А. Герцена. 2018;7(1):4–13. https://doi.org/10.17116/onkolog2018714-13</mixed-citation><mixed-citation xml:lang="en">Nyushko KM, Alekseev BYa, Krasheninnikov AA, Vorobyev NV, Safronova EYu, Kalpinsky AS, et al. Surgical treatment in patients with localized and locally advanced prostate cancer: results of a monocentric study. P.A. Herzen Journal of Oncology. 2018;7(1):4–13. (In Russ.). https://doi.org/10.17116/onkolog2018714-13</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 2001 Jan;165(1):119–125. https://doi.org/10.1097/00005392-200101000-00030</mixed-citation><mixed-citation xml:lang="en">Blute ML, Bergstralh EJ, Iocca A, Scherer B, Zincke H. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol. 2001 Jan;165(1):119–125. https://doi.org/10.1097/00005392-200101000-00030</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010; Nov;116(22):5226–5234. https://doi.org/10.1002/cncr.25456</mixed-citation><mixed-citation xml:lang="en">Cooperberg MR, Vickers AJ, Broering JM, Carroll PR. Comparative risk-adjusted mortality outcomes after primary surgery, radiotherapy, or androgen-deprivation therapy for localized prostate cancer. Cancer. 2010; Nov;116(22):5226–5234. https://doi.org/10.1002/cncr.25456</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Костин А. А., Кульченко Н. Г., Толкачев А. О. Рак предстательной железы. Принципы ранней диагностики. Вестник Российского университета дружбы народов. Серия: Медицина. 2016;(4):68–76.</mixed-citation><mixed-citation xml:lang="en">Kostin AA, Kulchenko NG, Tolkachev AO. Prostate cancer. Principles of early diagnosis. Bulletin of the Peoples’ Friendship University of Russia. Series: Medicine. 2016;(4):68–76. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Абоян И. А., Бадьян К. И., Грачев С. В., Галстян А. М., Лемешко С. И., Павлов Д. С. Рак предстательной железы: Актуальные вопросы стадирования и прогнозирования. Журнал фундаментальной медицины и биологии. 2016;(3):51–55.</mixed-citation><mixed-citation xml:lang="en">Aboyan IA, Badyan KI, Grachev SV, Galstyan AM, Lemeshko SI, Pavlov DS. Prostate cancer: current issues staging and prognostication. Journal of Fundamental Medicine and Biology. 2016;(3):51–55. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. JAMA. 1997 May;277(18):1445–1451.</mixed-citation><mixed-citation xml:lang="en">Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: a multi-institutional update. JAMA. 1997 May;277(18):1445–1451.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, et al. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 2000 Apr;55(4):572–577. https://doi.org/10.1016/s0090-4295(99)00479-3</mixed-citation><mixed-citation xml:lang="en">D’Amico AV, Whittington R, Malkowicz SB, Wu YH, Chen M, Art M, et al. Combination of the preoperative PSA level, biopsy gleason score, percentage of positive biopsies, and MRI T-stage to predict early PSA failure in men with clinically localized prostate cancer. Urology. 2000 Apr;55(4):572–577. https://doi.org/10.1016/s0090-4295(99)00479-3</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Gancarczyk KJ1, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology. 22003 Mar;61(3):589–595. https://doi.org/10.1016/s0090-4295(02)02287-2</mixed-citation><mixed-citation xml:lang="en">Gancarczyk KJ1, Wu H, McLeod DG, Kane C, Kusuda L, Lance R, et al. Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms. Urology. 22003 Mar;61(3):589–595. https://doi.org/10.1016/s0090-4295(02)02287-2</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Kattan MW, Vickers AJ, Yu C, Bianco FG, Cronin AM, Eastham JA, et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer. 2009 Mar;115(5):1005–1010. https://doi.org/10.1002/cncr.24083</mixed-citation><mixed-citation xml:lang="en">Kattan MW, Vickers AJ, Yu C, Bianco FG, Cronin AM, Eastham JA, et al. Preoperative and postoperative nomograms incorporating surgeon experience for clinically localized prostate cancer. Cancer. 2009 Mar;115(5):1005–1010. https://doi.org/10.1002/cncr.24083</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. Nov;117(22):5039–5046. https://doi.org/10.1002/cncr.26169</mixed-citation><mixed-citation xml:lang="en">Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: a straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer. Nov;117(22):5039–5046. https://doi.org/10.1002/cncr.26169</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Schroeck FR, Sun L, Freedland SJ, Jayachandran J, Robertson CN, Moul JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008;11(4):371–376. https://doi.org/10.1038/pcan.2008.18</mixed-citation><mixed-citation xml:lang="en">Schroeck FR, Sun L, Freedland SJ, Jayachandran J, Robertson CN, Moul JW. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008;11(4):371–376. https://doi.org/10.1038/pcan.2008.18</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Chun FK, Graefen M, Briganti A, Gallina A, Hopp J, et al. Initial biopsy outcome prediction – head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol. 2007 May;51(5):1236–1240; discussion 1241–1243. https://doi.org/10.1016/j.eururo.2006.07.021</mixed-citation><mixed-citation xml:lang="en">Chun FK, Graefen M, Briganti A, Gallina A, Hopp J, et al. Initial biopsy outcome prediction – head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol. 2007 May;51(5):1236–1240; discussion 1241–1243. https://doi.org/10.1016/j.eururo.2006.07.021</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Нюшко К. М., Перепухов В. М., Гаврилова В. Д., Алексеев Б. Я. Номограммы для прогнозирования вероятности развития биохимического рецидива у больных раком предстательной железы после проведенного хирургического лечения. Онкоурология. 2021;17(4):100–110. https://doi.org/10.17650/1726-9776-2021-17-4-100-110</mixed-citation><mixed-citation xml:lang="en">Nyushko KM, Perepukhov VM, Gavrilova VD, Alekseev BYa. Nomograms for predicting the risk of biochemical recurrence in patients with prostate cancer after surgery. Cancer Urology. 2021;17(4):100–110. (In Russ.). https://doi.org/10.17650/1726-9776-2021-17-4-100-110</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
